Clear All
12482 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
83858-0102-60 83858-0102 Dasatinib PHYRAGO 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug 1, 2024 In Use
70771-1903-06 70771-1903 Dasatinib Dasatinib 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 3, 2025 In Use
00480-5103-06 00480-5103 Dasatinib Dasatinib 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 18, 2025 In Use
43598-0604-30 43598-0604 Dasatinib Dasatinib 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 3, 2025 In Use
70377-0086-11 70377-0086 Dasatinib Dasatinib 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 3, 2025 In Use
00003-0855-22 00003-0855 Dasatinib Sprycel 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Oct 28, 2010 In Use
43598-0602-30 43598-0602 Dasatinib Dasatinib 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 3, 2025 In Use
00480-5104-56 00480-5104 Dasatinib Dasatinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 18, 2025 In Use
70748-0211-06 70748-0211 Dasatinib Dasatinib 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan 30, 2026 In Use
60505-3630-06 60505-3630 Dasatinib Dasatinib 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 3, 2024 In Use
43598-0601-60 43598-0601 Dasatinib Dasatinib 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 3, 2025 In Use
72603-0925-01 72603-0925 DASATINIB DASATINIB 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jun 1, 2026 In Use
43598-0600-60 43598-0600 Dasatinib Dasatinib 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 3, 2025 In Use
43598-0599-60 43598-0599 Dasatinib Dasatinib 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 3, 2025 In Use
72603-0926-01 72603-0926 DASATINIB DASATINIB 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jun 1, 2026 In Use
70377-0088-11 70377-0088 Dasatinib Dasatinib 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 3, 2025 In Use
00480-5101-06 00480-5101 Dasatinib Dasatinib 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 18, 2025 In Use
50419-0395-01 50419-0395 Darolutamide Nubeqa 300.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral Jul 31, 2019 In Use
50419-0395-72 50419-0395 Darolutamide Nubeqa 300.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral Mar 3, 2021 In Use
55513-0015-01 55513-0014 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Aug 19, 2002 Apr 30, 2009 No Longer Used
55513-0097-01 55513-0097 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Sep 25, 2006 Feb 28, 2009 No Longer Used
55513-0037-01 55513-0037 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Feb 18, 2011 Nov 30, 2008 No Longer Used
55513-0039-04 55513-0039 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Jul 23, 2003 Feb 28, 2009 No Longer Used
55513-0002-04 55513-0002 Darbepoetin alfa Aranesp 25.0 ug/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Sep 11, 2006 In Use
55513-0027-04 55513-0027 Darbepoetin alfa Aranesp 150.0 ug/.3mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Sep 11, 2006 In Use

Found 12482 results — Export these results